Announcement on Voluntary Shareholding Increase Plan by Certain Directors and Senior Management Members
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Voluntary Shareholding Increase Plan by Certain Directors and Senior Management Members
Filed with SSE · · 7 pages · Chinese
Release
Jiangsu Kanion Pharmaceutical Co. Ltd. on 6ix
Earlier from Jiangsu Kanion Pharmaceutical
- Report for Q3 2025
- Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice
- Announcement on Pledge of Some Shares Held by Shareholders with Over 5% Shares
- 2025 Semi-annual Report
- Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased Indications
Later from Jiangsu Kanion Pharmaceutical
- Announcement on Shareholding Increase by Persons Acting in Concert of Actual Controllers
- Announcement on the Inclusion of the Company’s Partial Drugs in the National Medical Insurance Catalog
- Announcement on Shareholding Increase Result of Some Directors and Senior Management Members
- Announcement on Cancelling the Board of Supervisors and Amending the Articles of Association and Some Governance Systems
- Announcement on Obtaining the Drug Registration Certificate for Xiebai San Granules
Follow Jiangsu Kanion Pharmaceutical into a list and get an email when it puts out news.
Follow Jiangsu Kanion Pharmaceutical